Compare SDGR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | CRVS |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2016 |
| Metric | SDGR | CRVS |
|---|---|---|
| Price | $19.71 | $14.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $21.00 | ★ $30.17 |
| AVG Volume (30 Days) | ★ 1.1M | 803.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.14 | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | N/A |
| Revenue This Year | $0.76 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $5.29 |
| 52 Week High | $23.02 | $26.95 |
| Indicator | SDGR | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 71.44 | 51.76 |
| Support Level | $17.26 | $14.24 |
| Resistance Level | N/A | $16.66 |
| Average True Range (ATR) | 0.89 | 0.73 |
| MACD | 0.23 | 0.04 |
| Stochastic Oscillator | 89.58 | 57.19 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.